These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 2076342)

  • 21. [Effects and side effects of transdermal scopolamine for premedication in general anesthesia in elderly patients].
    Tolksdorf W; Baumann S; Heine C; Hettenbach A
    Anasth Intensivther Notfallmed; 1986 Dec; 21(6):301-6. PubMed ID: 3544938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea.
    Attias J; Gordon C; Ribak J; Binah O; Rolnick A
    Aviat Space Environ Med; 1987 Jan; 58(1):60-2. PubMed ID: 3814034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modafinil as a potential motion sickness countermeasure.
    Hoyt RE; Lawson BD; McGee HA; Strompolis ML; McClellan MA
    Aviat Space Environ Med; 2009 Aug; 80(8):709-15. PubMed ID: 19653573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance.
    Gordon CR; Gonen A; Nachum Z; Doweck I; Spitzer O; Shupak A
    J Psychopharmacol; 2001 Sep; 15(3):167-72. PubMed ID: 11565623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate.
    Golding JF; Stott JR
    Br J Clin Pharmacol; 1997 Jun; 43(6):633-7. PubMed ID: 9205824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of scopolamine and cyclizine on visual-vestibular interaction in humans.
    Gowans J; Matheson A; Darlington CL; Smith PF
    J Vestib Res; 2000; 10(2):87-92. PubMed ID: 10939683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A reduction of vestibulo-visual integration during transdermally administered scopolamine and dimenhydrinate. A presentation of gain control theory in motion sickness.
    Pyykkö I; Schalén L; Jäntti V; Magnusson M
    Acta Otolaryngol Suppl; 1984; 406():167-73. PubMed ID: 6332454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Republic of Singapore Navy's Scopoderm TTS study: results after 2,200 man-days at sea.
    How J; Lee PS; Seet LC; Tan PK
    Aviat Space Environ Med; 1988 Jul; 59(7):646-50. PubMed ID: 3044323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of transdermally administered scopolamine on the vestibular system in humans.
    Shojaku H; Watanabe Y; Ito M; Mizukoshi K; Yajima K; Sekiguchi C
    Acta Otolaryngol Suppl; 1993; 504():41-5. PubMed ID: 8470531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Transdermally applied scopolamine for continuous prevention of motion sickness. Revival of a 150-year-old method].
    Becker G
    Schweiz Rundsch Med Prax; 1985 Mar; 74(11):271-6. PubMed ID: 3887535
    [No Abstract]   [Full Text] [Related]  

  • 31. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
    Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y
    Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of transdermal scopolamine on simulated ship navigation and attention/reaction time.
    Howland J; Rohsenow DJ; Minsky S; Snoberg J; Tagerud S; Hunt SK; Almeida A; Greece J; Allensworth-Davies D
    Int J Occup Environ Health; 2008; 14(4):250-6. PubMed ID: 19043911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Motion sickness at sea and in the air].
    Kuitunen T; Leino T; Parkkola K
    Duodecim; 2011; 127(13):1378-80. PubMed ID: 21834343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Clissold SP; Heel RC
    Drugs; 1985 Mar; 29(3):189-207. PubMed ID: 3886352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transderm scopolamine efficacy related to time of application prior to the onset of motion.
    Levy GD; Rapaport MH
    Aviat Space Environ Med; 1985 Jun; 56(6):591-3. PubMed ID: 4015572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transdermal scopolamine-induced psychosis.
    Ziskind AA
    Postgrad Med; 1988 Sep; 84(3):73-6. PubMed ID: 2901077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
    Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of double-dose transdermal scopolamine.
    Bar R; Gil A; Tal D
    Pharmacotherapy; 2009 Sep; 29(9):1082-8. PubMed ID: 19698013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of low-dose intranasal scopolamine for motion sickness.
    Simmons RG; Phillips JB; Lojewski RA; Wang Z; Boyd JL; Putcha L
    Aviat Space Environ Med; 2010 Apr; 81(4):405-12. PubMed ID: 20377145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of histaminergic drugs in experimental motion sickness.
    Matsnev EI; Sigaleva EE
    J Vestib Res; 2007; 17(5-6):313-21. PubMed ID: 18626141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.